Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors associated with the development of moderate to severe chronic graft-versus-host disease after non-myeloablative conditioning allogeneic stem cell transplantation in patients with AML or MDS.
Kok LMC, Bungener L, de Bock GH, Biswana A, van der Wal G, van Imhoff GW, Bellido M. Kok LMC, et al. Among authors: bellido m. Hum Cell. 2020 Jan;33(1):243-251. doi: 10.1007/s13577-019-00297-7. Epub 2019 Nov 15. Hum Cell. 2020. PMID: 31732859 Free PMC article.
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Herling M, Dearden C, Zaja F, El-Sharkawi D, Ding W, Bellido M, Khot A, Tick L, Jacobsen E, Eyre TA, Roos-Weil D, Kadia T, Lucchini E, Pflug N, Davids MS, Pena G, Mukherjee N, Badawi M, Vizkelety T, Staber PB. Herling M, et al. Among authors: bellido m. Blood Adv. 2024 Feb 27;8(4):842-845. doi: 10.1182/bloodadvances.2023012248. Blood Adv. 2024. PMID: 38190628 Free PMC article. Clinical Trial. No abstract available.
Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib.
van der Wagen L, Te Boome L, Schiffler M, Nijhof I, Schoordijk M, van Dorp S, van Dijk M, Raymakers R, Petersen E, de Witte M, de Jong N, Bellido M, Bär B, Meijer E, Kuball J. van der Wagen L, et al. Among authors: bellido m. Bone Marrow Transplant. 2018 Oct;53(10):1255-1262. doi: 10.1038/s41409-018-0158-9. Epub 2018 Mar 16. Bone Marrow Transplant. 2018. PMID: 29549292 Clinical Trial.
Improved Outcome of Allogeneic Transplantation in Older Patients Treated for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Reduced Duration of Immune Suppression.
Morsink LM, Hazenberg CLE, Choi G, de Groot MR, Biswana A, Bellido M, Kooistra HAM, Bungener LB, Meijer K, Mulder AB, Huls G. Morsink LM, et al. Among authors: bellido m. Transplant Cell Ther. 2024 Aug;30(8):794-807. doi: 10.1016/j.jtct.2024.05.009. Epub 2024 May 11. Transplant Cell Ther. 2024. PMID: 38740138 Free article.
Tyrosine kinase inhibitor levels matter in treating chronic GVHD.
van der Wagen L, Janssen J, Raijmakers R, Petersen E, de Witte M, de Jong N, Bellido M, Meijer E, Bär B, Jan Boelens J, Huitema A, Kuball J. van der Wagen L, et al. Among authors: bellido m. Bone Marrow Transplant. 2019 Jul;54(7):1141-1144. doi: 10.1038/s41409-018-0429-5. Epub 2019 Jan 16. Bone Marrow Transplant. 2019. PMID: 30651587 Clinical Trial. No abstract available.
Allogeneic Stem Cell Transplantation in Patients >40 Years of Age With Acute Lymphoblastic Leukemia: Reduced Intensity Versus Myeloablative Conditioning.
Sijs-Szabo A, Dinmohamed AG, Versluis J, van der Holt B, Bellido M, Hazenberg MD, van Gelder M, Schaap NPM, Meijer E, van der Wagen LE, Halkes CJM, Rijneveld AW, Cornelissen JJ. Sijs-Szabo A, et al. Among authors: bellido m. Transplantation. 2023 Dec 1;107(12):2561-2567. doi: 10.1097/TP.0000000000004706. Epub 2023 Jun 30. Transplantation. 2023. PMID: 37389645
Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study.
Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, Van der Kevie-Kersemaekers AM, Posthuma H, Rodriguez-Vicente AE, Tran AN, Barbany G, Mansouri L, Gunnarsson R, Parker H, Van den Berg E, Bellido M, Davis Z, Wall M, Scarpelli I, Österborg A, Hansson L, Jarosova M, Ghia P, Poddighe P, Espinet B, Pospisilova S, Tam C, Ysebaert L, Nguyen-Khac F, Oscier D, Haferlach C, Schoumans J, Stevens-Kroef M, Eldering E, Stamatopoulos K, Rosenquist R, Strefford JC, Mellink C, Kater AP. Leeksma AC, et al. Among authors: bellido m. Haematologica. 2021 Jan 1;106(1):87-97. doi: 10.3324/haematol.2019.239947. Haematologica. 2021. PMID: 31974198 Free PMC article.
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Saberi Hosnijeh F, van der Straten L, Kater AP, van Oers MHJ, Posthuma WFM, Chamuleau MED, Bellido M, Doorduijn JK, van Gelder M, Hoogendoorn M, de Boer F, Te Raa GD, Kerst JM, Marijt EWA, Raymakers RAP, Koene HR, Schaafsma MR, Dobber JA, Tonino SH, Kersting SS, Langerak AW, Levin MD. Saberi Hosnijeh F, et al. Among authors: bellido m. Exp Hematol. 2020 Sep;89:55-60.e6. doi: 10.1016/j.exphem.2020.08.002. Epub 2020 Aug 8. Exp Hematol. 2020. PMID: 32781097 Free article. Clinical Trial.
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Rijneveld AW, van der Holt B, de Weerdt O, Biemond BJ, van de Loosdrecht AA, van der Wagen LE, Bellido M, van Gelder M, van der Velden WJFM, Selleslag D, van Lammeren-Venema D, Halkes CJM, Fijnheer R, Havelange V, van Sluis GL, Legdeur MC, Deeren D, Gadisseur A, Sinnige HAM, Breems DA, Jaspers A, Legrand O, Terpstra WE, Boersma RS, Mazure D, Triffet A, Tick LW, Beel K, Maertens JA, Beverloo HB, Bakkus M, Homburg CHE, de Haas V, van der Velden VHJ, Cornelissen JJ; Dutch-Belgian HOVON Cooperative group. Rijneveld AW, et al. Among authors: bellido m. Blood Adv. 2022 Feb 22;6(4):1115-1125. doi: 10.1182/bloodadvances.2021005624. Blood Adv. 2022. PMID: 34883506 Free PMC article. Clinical Trial.
102 results